Valuation: MannKind Corporation

Market Cap 1.31B 1.14B 1.06B 973M 1.84B 125B 1.86B 12.45B 4.89B 62.33B 4.92B 4.81B 207B P/E 2026 *
31.5x
P/E 2027 * 14.6x
Enterprise Value 1.31B 1.14B 1.06B 973M 1.84B 125B 1.86B 12.45B 4.89B 62.33B 4.92B 4.81B 207B EV / Sales 2026 *
2.94x
EV / Sales 2027 * 2.54x
Free-Float
98.51%
Yield 2026 *
-
Yield 2027 * -
1 day-5.37%
1 week-5.60%
Current month-0.77%
1 month-9.13%
3 months+8.99%
6 months-32.87%
Current year-31.57%
1 week 3.69
Extreme 3.69
4.14
1 month 3.69
Extreme 3.69
4.41
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 25/05/2017
Director of Finance/CFO 50 22/04/2024
Chief Tech/Sci/R&D Officer - 29/09/2025
Director TitleAgeSince
Director/Board Member 82 01/10/2003
Director/Board Member 82 01/12/2003
Chairman 69 09/12/2020
Date Insider Type Main position Quantity % Market Cap.
17/7/26 Sell

General Counsel

-24,109 0.0078%
17/7/26 Sell

Director

-52,485 0.0170%
15/7/26 Fiscal year

Chief Executive Officer

1,063,720 0.3443%
Change 5-day change 1-year change 3-year change Capi.($)
-5.24%-5.60%+11.98%-15.65% 1.31B
-3.25%+12.81%+52.96%+88.86% 64.9B
+0.69%-2.81%+25.84%+68.41% 54.05B
-1.12%-2.44%-18.61%-8.04% 23.16B
+31.45%+28.50%+17.22%+496.32% 21.46B
+1.87%+5.08%+29.88%-7.94% 21.25B
-0.79%+1.79%+36.31%-26.13% 17.94B
-3.37%+19.44%+211.98%+369.13% 17.03B
+3.29%+2.09%+17.32%+586.49% 14.99B
-8.69%-6.72%+38.45%+157.83% 14.25B
Average +1.41%+3.68%+42.33%+170.93% 25.03B
Weighted average by Cap. +1.39%+3.66%+41.91%+146.19%

Financials

2026 *2027 *
Net sales 446M 387M 362M 331M 626M 42.47B 634M 4.24B 1.66B 21.22B 1.67B 1.64B 70.63B 515M 447M 418M 383M 722M 49.03B 732M 4.89B 1.92B 24.5B 1.93B 1.89B 81.53B
Net income 41.25M 35.8M 33.52M 30.66M 57.89M 3.93B 58.64M 392M 154M 1.96B 155M 152M 6.53B 91.3M 79.23M 74.19M 67.87M 128M 8.7B 130M 868M 341M 4.35B 343M 335M 14.46B
Net Debt - -
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
07/08/26 USD 3.880 -5.36% 8,112,541
05/08/26 USD 4.100 +3.54% 6,833,549
04/08/26 USD 3.960 +4.21% 5,118,134
03/08/26 USD 3.800 -2.81% 5,276,519
31/07/26 USD 3.910 -4.87% 5,404,120
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.100USD
Average target price
8.094USD
Spread / Average Target
+97.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNKD Stock